Prospects for cannabinoid therapies in basal ganglia disorders
Cannabinoids are promising medicines to slow down disease progression in neurodegenerative disorders including Parkinson's disease (PD) and Huntington's disease (HD), two of the most important disorders affecting the basal ganglia. Two pharmacological profiles have been proposed for cannab...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2011 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/93221 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/93221 |
| Access Level: | acceso abierto |
| Palabra clave: | 61 Basal ganglia Cannabinoid signalling system Cannabinoids CB1 receptors CB2 receptors Neurodegeneration Neuroprotection Ciencias Biomédicas Ciencias 24 Ciencias de la Vida |
| id |
ES_fd362e7588d67f5d9ee545f8f516f9ef |
|---|---|
| oai_identifier_str |
oai:docta.ucm.es:20.500.14352/93221 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Prospects for cannabinoid therapies in basal ganglia disordersFernández Ruiz, José JavierMoreno Martet, MiguelRodríguez Cueto, Carmen AuroraPalomo Garo, CristinaGómez Cañas, MaríaValdeolivas, SaraGuaza, CarmenRomero, JuliánGuzmán Pastor, ManuelMechoulam, RaphaelRamos Atance, José Antonio61Basal gangliaCannabinoid signalling systemCannabinoidsCB1 receptorsCB2 receptorsNeurodegenerationNeuroprotectionCiencias BiomédicasCiencias24 Ciencias de la VidaCannabinoids are promising medicines to slow down disease progression in neurodegenerative disorders including Parkinson's disease (PD) and Huntington's disease (HD), two of the most important disorders affecting the basal ganglia. Two pharmacological profiles have been proposed for cannabinoids being effective in these disorders. On the one hand, cannabinoids like Δ9‐tetrahydrocannabinol or cannabidiol protect nigral or striatal neurons in experimental models of both disorders, in which oxidative injury is a prominent cytotoxic mechanism. This effect could be exerted, at least in part, through mechanisms independent of CB1 and CB2 receptors and involving the control of endogenous antioxidant defences. On the other hand, the activation of CB2 receptors leads to a slower progression of neurodegeneration in both disorders. This effect would be exerted by limiting the toxicity of microglial cells for neurons and, in particular, by reducing the generation of proinflammatory factors. It is important to mention that CB2 receptors have been identified in the healthy brain, mainly in glial elements and, to a lesser extent, in certain subpopulations of neurons, and that they are dramatically up‐regulated in response to damaging stimuli, which supports the idea that the cannabinoid system behaves as an endogenous neuroprotective system. This CB2 receptor up‐regulation has been found in many neurodegenerative disorders including HD and PD, which supports the beneficial effects found for CB2 receptor agonists in both disorders. In conclusion, the evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB2receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation.Wiley Online LibraryUniversidad Complutense de Madrid20112011-01-0120112011-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/93221reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/932212026-06-02T12:44:21Z |
| dc.title.none.fl_str_mv |
Prospects for cannabinoid therapies in basal ganglia disorders |
| title |
Prospects for cannabinoid therapies in basal ganglia disorders |
| spellingShingle |
Prospects for cannabinoid therapies in basal ganglia disorders Fernández Ruiz, José Javier 61 Basal ganglia Cannabinoid signalling system Cannabinoids CB1 receptors CB2 receptors Neurodegeneration Neuroprotection Ciencias Biomédicas Ciencias 24 Ciencias de la Vida |
| title_short |
Prospects for cannabinoid therapies in basal ganglia disorders |
| title_full |
Prospects for cannabinoid therapies in basal ganglia disorders |
| title_fullStr |
Prospects for cannabinoid therapies in basal ganglia disorders |
| title_full_unstemmed |
Prospects for cannabinoid therapies in basal ganglia disorders |
| title_sort |
Prospects for cannabinoid therapies in basal ganglia disorders |
| dc.creator.none.fl_str_mv |
Fernández Ruiz, José Javier Moreno Martet, Miguel Rodríguez Cueto, Carmen Aurora Palomo Garo, Cristina Gómez Cañas, María Valdeolivas, Sara Guaza, Carmen Romero, Julián Guzmán Pastor, Manuel Mechoulam, Raphael Ramos Atance, José Antonio |
| author |
Fernández Ruiz, José Javier |
| author_facet |
Fernández Ruiz, José Javier Moreno Martet, Miguel Rodríguez Cueto, Carmen Aurora Palomo Garo, Cristina Gómez Cañas, María Valdeolivas, Sara Guaza, Carmen Romero, Julián Guzmán Pastor, Manuel Mechoulam, Raphael Ramos Atance, José Antonio |
| author_role |
author |
| author2 |
Moreno Martet, Miguel Rodríguez Cueto, Carmen Aurora Palomo Garo, Cristina Gómez Cañas, María Valdeolivas, Sara Guaza, Carmen Romero, Julián Guzmán Pastor, Manuel Mechoulam, Raphael Ramos Atance, José Antonio |
| author2_role |
author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universidad Complutense de Madrid |
| dc.subject.none.fl_str_mv |
61 Basal ganglia Cannabinoid signalling system Cannabinoids CB1 receptors CB2 receptors Neurodegeneration Neuroprotection Ciencias Biomédicas Ciencias 24 Ciencias de la Vida |
| topic |
61 Basal ganglia Cannabinoid signalling system Cannabinoids CB1 receptors CB2 receptors Neurodegeneration Neuroprotection Ciencias Biomédicas Ciencias 24 Ciencias de la Vida |
| description |
Cannabinoids are promising medicines to slow down disease progression in neurodegenerative disorders including Parkinson's disease (PD) and Huntington's disease (HD), two of the most important disorders affecting the basal ganglia. Two pharmacological profiles have been proposed for cannabinoids being effective in these disorders. On the one hand, cannabinoids like Δ9‐tetrahydrocannabinol or cannabidiol protect nigral or striatal neurons in experimental models of both disorders, in which oxidative injury is a prominent cytotoxic mechanism. This effect could be exerted, at least in part, through mechanisms independent of CB1 and CB2 receptors and involving the control of endogenous antioxidant defences. On the other hand, the activation of CB2 receptors leads to a slower progression of neurodegeneration in both disorders. This effect would be exerted by limiting the toxicity of microglial cells for neurons and, in particular, by reducing the generation of proinflammatory factors. It is important to mention that CB2 receptors have been identified in the healthy brain, mainly in glial elements and, to a lesser extent, in certain subpopulations of neurons, and that they are dramatically up‐regulated in response to damaging stimuli, which supports the idea that the cannabinoid system behaves as an endogenous neuroprotective system. This CB2 receptor up‐regulation has been found in many neurodegenerative disorders including HD and PD, which supports the beneficial effects found for CB2 receptor agonists in both disorders. In conclusion, the evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB2receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation. |
| publishDate |
2011 |
| dc.date.none.fl_str_mv |
2011 2011-01-01 2011 2011-01-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/20.500.14352/93221 |
| url |
https://hdl.handle.net/20.500.14352/93221 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley Online Library |
| publisher.none.fl_str_mv |
Wiley Online Library |
| dc.source.none.fl_str_mv |
reponame:Docta Complutense instname:Universidad Complutense de Madrid (UCM) |
| instname_str |
Universidad Complutense de Madrid (UCM) |
| reponame_str |
Docta Complutense |
| collection |
Docta Complutense |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869425519414476800 |
| score |
15,301603 |